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Abstract
SULT1A1, a member of sulfotransferase superfamily, is a drug and hormone metabolizing enzyme involved in the metabolism of a variety of
potential mammary carcinogens of endogenous and exogenous origin. Interestingly, the metabolic activity of SULT1A1 can be affected by varia-
tions in gene copy number. Male Breast Cancer (MBC) is a rare disease and less investigated disease compared to female BC (FBC). As in FBC,
the concurrent effects of genetic risk factors, particularly BRCA2 mutations, increased exposure to estrogens and environmental carcinogens
play a relevant role in MBC. By quantitative real-time PCR with TaqMan probes, we investigated the presence of SULT1A1 gene copy number
variations (CNVs) in a series of 72 MBCs. SULT1A1 gene deletion was observed in 10 of the 72 MBCs (13.9%). In a multivariate analysis associ-
ation between BRCA2 mutation and SULT1A1 gene deletion emerged (p = 0.0005). Based on the evidence that the level of SULT1A1 enzyme
activity is correlated with CNV, our data suggest that in male breast tumors SULT1A1 activity may be decreased. Thus, it can be hypothesized
that in a proportion of MBCs, particularly in BRCA2-associated MBCs, the level of estrogens and environmental carcinogens exposure might be
increased suggesting a link between gene and environmental exposure in the pathogenesis of MBC.
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SULT1A1, a member of sulfotransferase superfamily, is a drug and
hormone metabolizing enzyme involved in the metabolism of a variety
of potential mammary carcinogens of endogenous and exogenous
origin, including oestrogens and polycyclic aromatic hydrocarbons
(PAHs) [1].
Gene copy number variations (CNVs) are increasingly recognized to
play a relevant role in the expression of drug metabolizing genes and in
their respective enzymatic activities. In particular, the metabolic activity
of SULT1A1 can be affected by variations in gene copy number [2].
Male breast cancer (MBC) is a rare disease, compared with female
BC. The concurrent effects of genetic risk factors, particularly BRCA2
mutations, increased exposure to oestrogens and environmental car-
cinogens play a relevant role in MBC [3]. MBC is unaffected by the
strong confounding effects of high disease frequency and of repro-
duction-related variables, thus, the complex effects of genetic, hor-
monal and environmental factors, involved in the pathogenesis of BC
in both genders, can be better investigated in MBC.
On the basis of SULT1A1 biochemical properties, we investigated
the presence of SULT1A1 CNVs in a series of 72 MBCs characterized
for relevant clinical-pathologic features, including BRCA1/2 mutation
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Table 1 Distribution of 72 MBC cases according to SULT1A1 gene deletion and clinical-pathologic features
SULT1A1
Parameter* Deletion (%) No deletion (%) P value†
Family history of breast/ovarian cancer
Negative 4 (8.2) 45 (91.8) 0.06
Positive 6 (27.3) 16 (72.7)
Personal history of cancer
Negative 7 (11.7) 53 (88.3) 0.18
Positive 3 (27.3) 8 (72.7)
BRCA1 status
BRCA1 wt 10 (14.5) 59 (85.5)
BRCA1 mutation 0 (0) 2 (100.0) 1.0
BRCA2 status
BRCA2 wt 4 (6.3) 60 (93.7) <0.0001
BRCA2 mutation 6 (85.7) 1 (14.3)
ER
Negative 4 (40) 6 (60.0) 0.03‡
Positive 6 (9.7) 56 (90.3)
PR
Negative 4 (25.0) 12 (75.0) 0.12
Positive 6 (10.7) 50 (89.3)
HER2
Negative 5 (9.4) 48 (90.6) 0.12
Positive 4 (22.2) 14 (77.8)
Ki-67
Low 4 (10.0) 36 (90.0) 0.2
High 5 (16.1) 26 (83.9)
Histological grade
G1/G2 3 (6.8) 41 (93.2) 0.06
G3 6 (25.0) 18 (75.0)
Lymph node status
Negative 1 (3.9) 25 (96.2) 0.35
Positive 4 (14.3) 24 (85.7)
Total 10 (13.9) 62 (86.1)
*Some data for each parameter are not available.
†From Fisher exact test.
‡This association was not evident in a multivariate analysis.
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status [4]. SULT1A1 CNVs were analysed by quantitative real-time
PCR with TaqMan probes (Life Technologies, Carlsbad, CA, USA)
comparing DNAs from tumour and blood from each MBCs included in
the study. Normal breast tissue was used as calibrator sample. The
fold change in studied gene copy number, normalized to endogenous
control, was calculated using Relative Quantity (RQ) = 2DDCt.
SULT1A1 gene copy number differences were found to occur in
tumour compared with matched blood samples in 10 of the 72 MBCs
(13.9%). In particular, SULT1A1 gene deletion (RQ = 0.5) was
observed indicating the presence of a single copy of SULT1A1 gene in
the 10 tumour samples compared with two copies (RQ = 1) detected
in the corresponding blood samples. The results of blood and normal
breast tissue paired samples were comparable in each patient.
As shown in Table 1, statistically significant association emerged
between SULT1A1 gene deletion and BRCA2 mutations (P < 0.0001)
and ER-negative status (P = 0.03). However, in a multivariate analy-
sis only the association for BRCA2 status persisted (P = 0.0005).
To date, there are no data on CNVs of SULT1A1 gene in BC. We
found that a quite relevant proportion of MBCs (about 14%) showed
SULT1A1 gene deletion and, interestingly, that the deletion was
significantly found in BRCA2-associated tumours. Based on the evi-
dence that the level of SULT1A1 enzyme activity is correlated with
CNV [2], our data suggest that in male breast tumours SULT1A1
activity may be decreased.
It has been reported that oestrogen sulfotransferases are fre-
quently decreased in breast carcinomas and this may result in an
increased exposure of mammary tissue to oestrogens [5]. Very
recently, SULT1A1 has been shown to play an important role in the
detoxication of PAHs in lung cells [6]. Thus, based on our results, it
can be suggested that in a proportion of MBCs, particularly in
BRCA2-associated MBCs, the level of oestrogens and environmental
carcinogens exposure might be increased. This could be particular
relevant considering the important role of oestrogens in MBC patho-
genesis and the molecular crosstalk between oestrogens and BRCA2
gene [7]. Intriguingly, we have previously shown an interaction
between BRCA carrier status and occupational exposure to chemicals,
such as PAHs, in MBC patients [8]. Thus, our present results may
help to clarify possible pathogenetic mechanisms underlying this
interaction.
Overall, our data suggest that MBCs, particularly BRCA2-associ-
ated MBCs, may be characterized by low SULT1A1A enzymatic activ-
ity thus suggesting a link between gene and environmental exposure
and opening interesting questions on clinical settings.
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